X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14891) 14891
Magazine Article (21) 21
Book Chapter (9) 9
Dissertation (4) 4
Newsletter (3) 3
Publication (3) 3
Book / eBook (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8294) 8294
male (8173) 8173
animals (7823) 7823
imidazoles - pharmacology (6351) 6351
female (5699) 5699
imidazoles - administration & dosage (5611) 5611
imidazoles - therapeutic use (4037) 4037
rats (3588) 3588
middle aged (3056) 3056
adult (2661) 2661
aged (2346) 2346
mice (2193) 2193
pharmacology & pharmacy (2185) 2185
imidazoles - adverse effects (1921) 1921
dose-response relationship, drug (1806) 1806
oncology (1549) 1549
treatment outcome (1360) 1360
time factors (1355) 1355
administration, oral (1256) 1256
blood pressure - drug effects (1243) 1243
rats, sprague-dawley (1160) 1160
pyridines - pharmacology (1094) 1094
zoledronic acid (1040) 1040
diphosphonates - administration & dosage (972) 972
imidazoles - pharmacokinetics (952) 952
cancer (917) 917
analysis (867) 867
diphosphonates - therapeutic use (852) 852
disease models, animal (830) 830
dogs (802) 802
research (792) 792
rats, wistar (780) 780
drug therapy, combination (779) 779
double-blind method (761) 761
cell line, tumor (715) 715
apoptosis (708) 708
imidazoles - chemistry (704) 704
expression (688) 688
tetrazoles - pharmacology (685) 685
care and treatment (680) 680
adolescent (678) 678
heart rate - drug effects (666) 666
aged, 80 and over (663) 663
drug therapy (663) 663
neurosciences (661) 661
drug administration schedule (656) 656
bisphosphonates (654) 654
medicine & public health (633) 633
hypertension - drug therapy (610) 610
bone density conservation agents - administration & dosage (607) 607
therapy (590) 590
bone density conservation agents - therapeutic use (588) 588
enzyme inhibitors - pharmacology (587) 587
losartan (587) 587
diphosphonates - adverse effects (583) 583
health aspects (576) 576
inhibition (576) 576
veterinary sciences (574) 574
biochemistry & molecular biology (571) 571
hypertension (564) 564
endocrinology & metabolism (556) 556
imidazoles - metabolism (529) 529
double-blind (528) 528
injections, intravenous (521) 521
diphosphonates - pharmacology (513) 513
clinical trials as topic (512) 512
apoptosis - drug effects (510) 510
angiotensin receptor antagonists (505) 505
cell biology (499) 499
in-vitro (497) 497
mice, inbred c57bl (497) 497
cells, cultured (496) 496
imidazoles (491) 491
administration, topical (481) 481
efficacy (481) 481
activation (480) 480
peripheral vascular disease (479) 479
osteoporosis (476) 476
hemodynamics - drug effects (470) 470
research article (469) 469
antihypertensive agents - pharmacology (466) 466
bone neoplasms - secondary (464) 464
imidazoles - toxicity (463) 463
in vitro techniques (463) 463
rabbits (459) 459
pharmacokinetics (449) 449
cells (439) 439
proteins (439) 439
bone density conservation agents - adverse effects (433) 433
rodents (430) 430
pharmacology (426) 426
urology & nephrology (420) 420
drug interactions (418) 418
imidazoles - blood (411) 411
toxicology (410) 410
physiology (409) 409
cell proliferation - drug effects (407) 407
medetomidine (406) 406
infusions, intravenous (405) 405
tetrazoles - administration & dosage (404) 404
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14158) 14158
German (318) 318
Japanese (275) 275
Russian (135) 135
French (112) 112
Italian (53) 53
Spanish (53) 53
Chinese (34) 34
Polish (21) 21
Portuguese (19) 19
Dutch (16) 16
Hungarian (14) 14
Danish (11) 11
Czech (8) 8
Bulgarian (7) 7
Swedish (7) 7
Norwegian (4) 4
Turkish (3) 3
Croatian (2) 2
Hebrew (2) 2
Lithuanian (2) 2
Romanian (2) 2
Serbian (2) 2
Slovak (2) 2
Finnish (1) 1
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 6, pp. 1511 - 1522
Summary Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment... 
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Treatment | Resistance-associated variants | Ledipasvir | Interferon | Hepatitis C virus | Sofosbuvir | Direct-acting antivirals | Resistanceassociated variants | CHRONIC HCV | CHRONIC HEPATITIS-C | REAL-WORLD | PEGYLATED INTERFERON | DOUBLE-BLIND | GENOTYPE 1 INFECTION | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | DACLATASVIR PLUS SOFOSBUVIR | Uridine Monophosphate - administration & dosage | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Carbamates - administration & dosage | Simeprevir - administration & dosage | Uracil - administration & dosage | Benzimidazoles - administration & dosage | Ribavirin - administration & dosage | Treatment Failure | Protease Inhibitors - administration & dosage | Fluorenes - administration & dosage | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Clinical Trials as Topic | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Interferons - administration & dosage | Drug Resistance, Viral - genetics | Anilides - administration & dosage | Sofosbuvir - administration & dosage | Uridine Monophosphate - analogs & derivatives | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Development and progression | Protease inhibitors | Drug resistance | Hepatitis C | Proteases
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Journal of internal medicine, ISSN 0954-6820, 2015, Volume 277, Issue 6, pp. 690 - 706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence... 
calcium | vitamin D | strontium | bisphosphonate | SERM | osteoporosis | denosumab | Strontium | Osteoporosis | Bisphosphonate | Calcium | Vitamin D | Denosumab | BONE-MINERAL DENSITY | ORAL BISPHOSPHONATES | VITAMIN-D-RECEPTOR | ELDERLY-WOMEN | RANDOMIZED CONTROLLED-TRIAL | ZOLEDRONIC ACID | CALCIUM SUPPLEMENTATION | MEDICINE, GENERAL & INTERNAL | CLINICAL-TRIALS | PLACEBO-CONTROLLED TRIAL | HEALTHY POSTMENOPAUSAL WOMEN | Etidronic Acid - administration & dosage | Bone Density Conservation Agents - adverse effects | Osteoporosis - prevention & control | Risk Assessment | Teriparatide - administration & dosage | Humans | Osteoporotic Fractures - prevention & control | Imidazoles - administration & dosage | Treatment Outcome | Diphosphonates - administration & dosage | Thiophenes - administration & dosage | Bone Density Conservation Agents - administration & dosage | Evidence-Based Medicine | Calcium Compounds - administration & dosage | Spinal Fractures - prevention & control | Antibodies, Monoclonal, Humanized - administration & dosage | Raloxifene Hydrochloride - administration & dosage | Hip Fractures - prevention & control | Vitamin D - administration & dosage | Risedronate Sodium | Diphosphonates - adverse effects | Etidronic Acid - analogs & derivatives | Alendronate - administration & dosage | Prevention | Calcifediol | Alfacalcidol | Analysis
Journal Article
Annals of oncology, ISSN 0923-7534, 2015, Volume 26, Issue 2, pp. 313 - 320
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
PloS one, ISSN 1932-6203, 02/2016, Volume 11, Issue 2, p. e0148984
.... Based on their complementary signalling pathways, we assessed humoral immune responses to model antigens after co-administration with the toll-like receptor 4 (TLR4... 
PATHWAYS | IMMUNIZATION | RESPONSES | DENDRITIC CELLS | PROTECTION | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | MUCOSAL | LIGAND | SECRETION | EXPRESSION | HIV Antibodies - blood | Antibody Specificity | Adjuvants, Immunologic - administration & dosage | Immunoglobulin G - blood | Toll-Like Receptor 8 - administration & dosage | Lipid A - analogs & derivatives | AIDS Vaccines - immunology | Immunity, Mucosal - drug effects | Toll-Like Receptor 8 - immunology | 1,2-Dipalmitoylphosphatidylcholine - administration & dosage | Immunoglobulin G - biosynthesis | Swine | HIV Antibodies - biosynthesis | Toll-Like Receptor 4 - agonists | Models, Animal | Lipid A - administration & dosage | Antibody Affinity | Toll-Like Receptor 4 - immunology | Lipid A - pharmacology | Toll-Like Receptor 7 - administration & dosage | 1,2-Dipalmitoylphosphatidylcholine - pharmacology | AIDS Vaccines - administration & dosage | Adjuvants, Immunologic - pharmacology | Dose-Response Relationship, Immunologic | env Gene Products, Human Immunodeficiency Virus - immunology | Vagina - immunology | Imidazoles - administration & dosage | Neutralization Tests | Toll-Like Receptor 4 - administration & dosage | Antigens - administration & dosage | Immunization, Secondary | Vaccination - methods | HIV Antibodies - immunology | Immunoglobulin G - immunology | Toll-Like Receptor 7 - immunology | Swine, Miniature | Female | Injections, Intradermal | Toll-Like Receptor 8 - agonists | Toll-Like Receptor 7 - agonists | Immunity, Innate | Organ Specificity | Administration, Intranasal | Animals | Nasal Mucosa - immunology | env Gene Products, Human Immunodeficiency Virus - administration & dosage | Antigens - immunology | Imidazoles - antagonists & inhibitors | Drug Combinations | Physiological aspects | Toll-like receptors | Genetic aspects | Immune response | Research | Animal models | Mucosal immunity | Mucosa | Immunoglobulin G | Infections | Vaccines | Immunity | Proteins | Signal transduction | Inoculation | Immunology | Pathways | Rodents | Human immunodeficiency virus--HIV | Immunity (humoral) | Immune system | Antigens | Medical research | TLR7 protein | Vagina | Priming | Glycoproteins | TLR4 protein | Gene expression | Immune response (humoral) | Medicine | Signaling | Infectious diseases | Ligands | HIV | Human immunodeficiency virus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors
Journal Article
The lancet oncology, ISSN 1470-2045, 2008, Volume 9, Issue 9, pp. 840 - 849
Journal Article